Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Are Hematologic Patients Trojan Horse for COVID-19?
Kılıçaslan E, Erdoğan Özünal I, Elibol T, Öztürk E. Kılıçaslan E, et al. Among authors: erdogan ozunal i. Indian J Hematol Blood Transfus. 2022 Jul;38(3):529-535. doi: 10.1007/s12288-021-01498-7. Epub 2021 Oct 15. Indian J Hematol Blood Transfus. 2022. PMID: 34667375 Free PMC article.
A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.
Ozturk E, Erdogan Ozunal I. Ozturk E, et al. Among authors: erdogan ozunal i. Medeni Med J. 2021;36(2):176-179. doi: 10.5222/MMJ.2021.56424. Epub 2021 Jun 18. Medeni Med J. 2021. PMID: 34239769 Free PMC article.
Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?
Koçak Göktürk I, Erdoğan Özünal I, Göktürk A, Kaya AH, Yılmaz G, Akay OM, Öztürk E. Koçak Göktürk I, et al. Among authors: erdogan ozunal i. Turk J Haematol. 2023 Feb 28;40(1):37-42. doi: 10.4274/tjh.galenos.2023.2022.0452. Turk J Haematol. 2023. PMID: 36847696 Free PMC article.
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
Ongoren S, Eskazan AE, Suzan V, Savci S, Erdogan Ozunal I, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Erbilgin Y, Iseri SA, Ar MC, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Ongoren S, et al. Among authors: erdogan ozunal i. Hematology. 2018 May;23(4):212-220. doi: 10.1080/10245332.2017.1385193. Epub 2017 Oct 9. Hematology. 2018. PMID: 28990873 Free article. Review.
The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
Soysal T, Eskazan AE, Serin I, Sadri S, Keskin D, Ozgur Yurttas N, Berk S, Erdogan Ozunal I, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Ozbek U, Aydin Y. Soysal T, et al. Among authors: erdogan ozunal i. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e377-e384. doi: 10.1016/j.clml.2019.03.028. Epub 2019 Apr 4. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31088736